What is BioSafe Technologies?
Founded in 2000, BioSafe Technologies, Inc. operates at the intersection of biotechnology and consumer health, specializing in the development of non-toxic pesticide formulations. The company has carved out a distinct niche by addressing the demand for safe, effective treatments against parasites and blood-sucking insects. Their flagship product line, which includes clinically validated lice shampoos, serves as a cornerstone for their export-heavy business model. By focusing on private labeling partnerships with major pharmaceutical entities, BioSafe effectively navigates complex international regulatory landscapes, ensuring their innovative insect control products reach diverse global markets efficiently.
How much funding has BioSafe Technologies raised?
BioSafe Technologies has raised a total of $29K across 1 funding round:
Debt
$29K
Debt (2021): $29K with participation from PPP
Key Investors in BioSafe Technologies
PPP
Public-Private Partnership
What's next for BioSafe Technologies?
With the recent influx of capital, BioSafe Technologies is poised to transition into a more aggressive growth phase. The company's strategic roadmap likely involves deepening its penetration into European markets while exploring new regulatory approvals in additional territories. As a woman-owned enterprise, BioSafe continues to prioritize innovation in sustainable pest management, aiming to capitalize on the rising global consumer preference for chemical-free health solutions. Future efforts will likely focus on scaling manufacturing capabilities and expanding the portfolio of non-toxic applications to address broader public health challenges in both human and veterinary sectors.
See full BioSafe Technologies company page
